-
-
Overview
-
Specificity: Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Obinutuzumab/afutuzumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
Obinutuzumab biosimilar is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells. The molecular mass of the antibody is approximately 150 kDa. it is produced by mammalian cell (CHO) suspension culture. It was engineered for reduced fucose content as compared to a typical IgG1 produced in CHO cells.
-
- Properties
-
Overview